Disfunzione erettile nella sclerosi multipla. Risultati clinici del trattamento con Sildenafil

Translated title of the contribution: Erectil dysfunction in multiple sclerosis. Clinical data on the treatment with Sildenafil

Angelo Ghezzi, Silvana Maria Baldini, Gian Mario Malvestiti, Vittorio Martinelli, Enrico Montanari, Antonio Savino, Mauro Zaffaroni, Adelio Zibetti

Research output: Contribution to journalArticle

Abstract

Sildenafil is an effective drug for erectile dysfunction (ED) of various causes, including neurological diseases. We evaluated the efficacy of sildenafil in an open collaborative study of patients affected by multiple sclerosis (MS). Forty patients affected by MS (mean age 43.7±8.3 years, mean disease duration 10.3±6.9 years) complaining of ED for at least 6 months (mean duration of ED 3.8±2.1 years) were studied. ED was scored by the International Index of Erectile Function-5 (IIEF-5). Sildenafil was given at a fixed dose of 50 mg., taken 1 hour before sexual activity. Results to treatment were evaluated after 8 administrations/after 3 months, asking the patients if the scores of at least 4 questions increased. The same evaluation was conducted on patient's partners. Four patients had no sexual activity in the following 3 months and did not answer to the questionnaire. The mean basal score of the IIEF-5 was 11±4.7, ranging fron 6 to 18; ED was diagnosed if IIEF-5 score was

Original languageItalian
Pages (from-to)157-161
Number of pages5
JournalRivista di Neurobiologia
Volume47
Issue number3
Publication statusPublished - 2001

Fingerprint

Erectile Dysfunction
Multiple Sclerosis
Sexual Behavior
Therapeutics
Sildenafil Citrate
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Ghezzi, A., Baldini, S. M., Malvestiti, G. M., Martinelli, V., Montanari, E., Savino, A., ... Zibetti, A. (2001). Disfunzione erettile nella sclerosi multipla. Risultati clinici del trattamento con Sildenafil. Rivista di Neurobiologia, 47(3), 157-161.

Disfunzione erettile nella sclerosi multipla. Risultati clinici del trattamento con Sildenafil. / Ghezzi, Angelo; Baldini, Silvana Maria; Malvestiti, Gian Mario; Martinelli, Vittorio; Montanari, Enrico; Savino, Antonio; Zaffaroni, Mauro; Zibetti, Adelio.

In: Rivista di Neurobiologia, Vol. 47, No. 3, 2001, p. 157-161.

Research output: Contribution to journalArticle

Ghezzi, A, Baldini, SM, Malvestiti, GM, Martinelli, V, Montanari, E, Savino, A, Zaffaroni, M & Zibetti, A 2001, 'Disfunzione erettile nella sclerosi multipla. Risultati clinici del trattamento con Sildenafil', Rivista di Neurobiologia, vol. 47, no. 3, pp. 157-161.
Ghezzi A, Baldini SM, Malvestiti GM, Martinelli V, Montanari E, Savino A et al. Disfunzione erettile nella sclerosi multipla. Risultati clinici del trattamento con Sildenafil. Rivista di Neurobiologia. 2001;47(3):157-161.
Ghezzi, Angelo ; Baldini, Silvana Maria ; Malvestiti, Gian Mario ; Martinelli, Vittorio ; Montanari, Enrico ; Savino, Antonio ; Zaffaroni, Mauro ; Zibetti, Adelio. / Disfunzione erettile nella sclerosi multipla. Risultati clinici del trattamento con Sildenafil. In: Rivista di Neurobiologia. 2001 ; Vol. 47, No. 3. pp. 157-161.
@article{e8e12e8c094145af85c6fe4b961f2df9,
title = "Disfunzione erettile nella sclerosi multipla. Risultati clinici del trattamento con Sildenafil",
abstract = "Sildenafil is an effective drug for erectile dysfunction (ED) of various causes, including neurological diseases. We evaluated the efficacy of sildenafil in an open collaborative study of patients affected by multiple sclerosis (MS). Forty patients affected by MS (mean age 43.7±8.3 years, mean disease duration 10.3±6.9 years) complaining of ED for at least 6 months (mean duration of ED 3.8±2.1 years) were studied. ED was scored by the International Index of Erectile Function-5 (IIEF-5). Sildenafil was given at a fixed dose of 50 mg., taken 1 hour before sexual activity. Results to treatment were evaluated after 8 administrations/after 3 months, asking the patients if the scores of at least 4 questions increased. The same evaluation was conducted on patient's partners. Four patients had no sexual activity in the following 3 months and did not answer to the questionnaire. The mean basal score of the IIEF-5 was 11±4.7, ranging fron 6 to 18; ED was diagnosed if IIEF-5 score was",
keywords = "Erectile dysfunction, Multiple sclerosis, Sildenafil",
author = "Angelo Ghezzi and Baldini, {Silvana Maria} and Malvestiti, {Gian Mario} and Vittorio Martinelli and Enrico Montanari and Antonio Savino and Mauro Zaffaroni and Adelio Zibetti",
year = "2001",
language = "Italian",
volume = "47",
pages = "157--161",
journal = "Rivista Italiana di Neurobiologia",
issn = "0035-6336",
publisher = "Editrice Pisani s.a.s.",
number = "3",

}

TY - JOUR

T1 - Disfunzione erettile nella sclerosi multipla. Risultati clinici del trattamento con Sildenafil

AU - Ghezzi, Angelo

AU - Baldini, Silvana Maria

AU - Malvestiti, Gian Mario

AU - Martinelli, Vittorio

AU - Montanari, Enrico

AU - Savino, Antonio

AU - Zaffaroni, Mauro

AU - Zibetti, Adelio

PY - 2001

Y1 - 2001

N2 - Sildenafil is an effective drug for erectile dysfunction (ED) of various causes, including neurological diseases. We evaluated the efficacy of sildenafil in an open collaborative study of patients affected by multiple sclerosis (MS). Forty patients affected by MS (mean age 43.7±8.3 years, mean disease duration 10.3±6.9 years) complaining of ED for at least 6 months (mean duration of ED 3.8±2.1 years) were studied. ED was scored by the International Index of Erectile Function-5 (IIEF-5). Sildenafil was given at a fixed dose of 50 mg., taken 1 hour before sexual activity. Results to treatment were evaluated after 8 administrations/after 3 months, asking the patients if the scores of at least 4 questions increased. The same evaluation was conducted on patient's partners. Four patients had no sexual activity in the following 3 months and did not answer to the questionnaire. The mean basal score of the IIEF-5 was 11±4.7, ranging fron 6 to 18; ED was diagnosed if IIEF-5 score was

AB - Sildenafil is an effective drug for erectile dysfunction (ED) of various causes, including neurological diseases. We evaluated the efficacy of sildenafil in an open collaborative study of patients affected by multiple sclerosis (MS). Forty patients affected by MS (mean age 43.7±8.3 years, mean disease duration 10.3±6.9 years) complaining of ED for at least 6 months (mean duration of ED 3.8±2.1 years) were studied. ED was scored by the International Index of Erectile Function-5 (IIEF-5). Sildenafil was given at a fixed dose of 50 mg., taken 1 hour before sexual activity. Results to treatment were evaluated after 8 administrations/after 3 months, asking the patients if the scores of at least 4 questions increased. The same evaluation was conducted on patient's partners. Four patients had no sexual activity in the following 3 months and did not answer to the questionnaire. The mean basal score of the IIEF-5 was 11±4.7, ranging fron 6 to 18; ED was diagnosed if IIEF-5 score was

KW - Erectile dysfunction

KW - Multiple sclerosis

KW - Sildenafil

UR - http://www.scopus.com/inward/record.url?scp=0035733807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035733807&partnerID=8YFLogxK

M3 - Articolo

VL - 47

SP - 157

EP - 161

JO - Rivista Italiana di Neurobiologia

JF - Rivista Italiana di Neurobiologia

SN - 0035-6336

IS - 3

ER -